Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Opioid    symbols : SRNE    save search

Nutriband Supports Newly Published CDC Opioid Prescribing Guidelines
Published: 2022-11-08 (Crawled : 12:00) - nutriband.com
NTRB | $4.04 18K twitter stocktwits trandingview |
Manufacturing
| | O: -6.56% H: 6.78% C: -0.73%
SRNE | $0.024 57K twitter stocktwits trandingview |
Health Technology
| | O: 1.38% H: 2.72% C: 0.0%

guidelines opioid
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial
Published: 2021-12-09 (Crawled : 22:00) - biospace.com/
SRNE | $0.024 57K twitter stocktwits trandingview |
Health Technology
| | O: 1.03% H: 2.75% C: -2.6%

sp-102 trial therapeutics opioid positive results phase 3 topline
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the Potential Use of SP-102 as a Best-in-Class Therapy
Published: 2021-12-09 (Crawled : 17:00) - globenewswire.com
SRNE | $0.024 57K twitter stocktwits trandingview |
Health Technology
| | O: 1.03% H: 2.75% C: -2.6%

sp-102 trial therapeutics potential opioid positive therapy results phase 3 topline
Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management
Published: 2021-07-20 (Crawled : 17:00) - globenewswire.com
SRNE | $0.024 57K twitter stocktwits trandingview |
Health Technology
| | O: 1.58% H: 1.39% C: 0.25%

opioid phase 3 trial injection enroll
FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients
Published: 2021-07-06 (Crawled : 19:00) - globenewswire.com
SRNE | $0.024 57K twitter stocktwits trandingview |
Health Technology
| | O: -1.05% H: 1.06% C: -12.02%

treatment fda phase 2 opioid osteoarthritis trial fda clearance
Gainers vs Losers
71% 29%

Top 10 Gainers
AGBA | News | $1.27 217.5% 120M twitter stocktwits trandingview |
Finance

EGOX | $0.0503 39.72% 320M twitter stocktwits trandingview |

RWOD | $10.52 31.56% 5.9M twitter stocktwits trandingview |
n/a

ZCMD | $1.905 31.38% 30M twitter stocktwits trandingview |
Commercial Services

MRDB 4 | $0.536 27.65% 2M twitter stocktwits trandingview |
n/a

BSFC | $0.0822 27.64% 75M twitter stocktwits trandingview |
Manufacturing

TPET | $0.4121 25.68% 45M twitter stocktwits trandingview |
n/a

NVFY | $2.65 25.59% 33M twitter stocktwits trandingview |
Consumer Durables

INDO | $5.1 25.0% 15M twitter stocktwits trandingview |
Energy Minerals

CHRO | $1.53 24.9% 100K twitter stocktwits trandingview |
n/a


Your saved searches
Save your searches and get alerts when important news are released.